Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Naproxen Tables, 375 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.) |
| 2 | ACTIVE_COMPARATOR | Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.) |
| Name | Type | Description |
|---|---|---|
| Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.) | DRUG | - |
| Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.) | DRUG | - |
Inclusion Criteria: * No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: * Positive test results for HIV or hepatitis B or C. * Treatment for drug or alcohol dependence.
Top 20 of 26 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Adalimumab, Upadacitinib, Lutikizumab, Ravagalimab |
| Bristol-Myers Squibb Company | BMY | 6 | PHASE3 | Abatacept, Zolacabtagene autoleucel, BMS-986528, BMS-986454 |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Baricitinib, LY4213663, LY4298445 |
| Johnson & Johnson | JNJ | 1 | PHASE3 | Guselkumab |
| AstraZeneca PLC | AZN | 4 | PHASE2 | AZD1163, AZD0120, AZD5492, Surovatamig |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE2 | Ianalumab, PIT565, Secukinumab |
| Merck & Co., Inc. | MRK | 2 | PHASE2 | Tulisokibart, MK-1045 |
| AnaptysBio, Inc. | ANAB | 1 | PHASE2 | Rosnilimab |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY002-072 |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | Sarilumab, SAR448501 |
| Immunovant Inc | IMVT | 1 | PHASE2 | IMVT-1402 |
| XBiotech, Inc. | XBIT | 1 | PHASE2 | Natrunix |
| Amgen Inc. | AMGN | 1 | PHASE2 | Inebilizumab, Blinatumomab |
| Artiva Biotherapeutics, Inc. | ARTV | 2 | PHASE2 | AB-101 |
| Gilead Sciences, Inc. | GILD | 1 | PHASE1 | GS-0151 |
| Cullinan Therapeutics, Inc. | CGEM | 1 | PHASE1 | CLN-978 |
| Xencor, Inc. | XNCR | 1 | PHASE1 | Plamotamab |
| Adicet Bio Inc | ACET | 1 | PHASE1 | ADI-001 |
| Pfizer Inc. | PFE | 2 | - | tofacitinib |
| Jade Biosciences, Inc. | JBIO | 1 | PHASE1 | JADE201 |
Naproxen Tablets, 375 is a 375 mg delayed-release oral formulation of naproxen studied for rheumatoid arthritis. It is also referenced in osteoarthritis research. The drug is a small molecule in the immunology therapeutic area and has been evaluated in a Phase 1 relative bioavailability study.
Naproxen Tablets, 375 targets PTGS2 and PTGS1, also known as cyclooxygenase-2 and cyclooxygenase-1. It acts as an inhibitor of these enzymes. This target class is consistent with the drug's development for inflammatory joint conditions such as rheumatoid arthritis.
Novartis AG (ticker: NVS) is the developer of Naproxen Tablets, 375. The alternative name Naproxen Delayed Release Tablets, 375 is associated with Gevena Pharmaceuticals, Inc. The asset is a small molecule in the immunology therapeutic area.
Naproxen Tablets, 375 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 1 program includes one completed trial with 34 participants.
Naproxen Tablets, 375 has been studied in one completed Phase 1 trial, NCT00959439, titled Relative Bioavailability Study of Naproxen Delayed-Release Tablets (375 mg). The trial enrolled 34 participants, was randomized, active-controlled, and included healthy volunteers. It evaluated rheumatoid arthritis and osteoarthritis conditions.
Yes, Naproxen Tablets, 375 is also known as Naproxen Delayed Release Tablets, 375, associated with Gevena Pharmaceuticals, Inc. Both names refer to the same 375 mg delayed-release naproxen formulation developed by Novartis AG for rheumatoid arthritis.